摘要 |
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin alpha<SUB>v</SUB>beta<SUB>5 </SUB>antagonists. The alpha<SUB>v</SUB>beta<SUB>5</SUB>-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-alpha and epidermal growth factor. Inhibition of alpha<SUB>v</SUB>beta<SUB>5</SUB>-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing alpha<SUB>v</SUB>beta<SUB>5 </SUB>antagonists.
|